Nasdaq

Clene, Inc. Announces Significant Survival Benefit of CNM-Au8® for ALS Patients in New Post Hoc Analysis

Clene, Inc. reports significant survival benefits from CNM-Au8® treatment for ALS in recent survival analyses from the HEALEY trial. Clene, Inc. announced promising results from a post hoc analysis of ...
Nasdaq

Clene Inc. Plans NDA Submission for CNM-Au8® in ALS and Initiates Phase 3 RESTORE-ALS Trial in 2025

Clene plans to submit a New Drug Application for CNM-Au8 in ALS by late 2025 and initiate a Phase 3 trial. Clene Inc. announced its plans to submit a New Drug Application (NDA) for CNM-Au8® for ...